Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iAPA-DC/CTL plus gemcitabine for advanced pancreatic cancer
ChiCTR-IPR-15006946Phase 2Recruiting
- Sponsor
- Changhai Hospital
- Start
- Jun 2015
- Modality
- Small Molecules, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of iAPA-DC + CTL and gemcitabine in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Changhai Hospital. Primary endpoint: 6-month survival rate. Started Jun 2015; status: recruiting.
02
Drugs
iAPA-DC + CTLgemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ChiCTR-IPR-15006946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-15006946.